OAS1 gene haplotype confers susceptibility to multiple sclerosis

Tissue Antigens

Volumn 68, Issue 5, 2006, Pages 446-449

  Fedetz, M ^a   Matesanz, F ^a   Caro Maldonado, A ^a   Fernandez, O ^b   Tamayo, J A ^b   Guerrero, M ^c   Delgado, C ^d   Lopez Guerrero J A ^e   Alcina, A ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d Ctro Reg de Transfus Sanguinea   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

2 ,5 oligoadenylate synthetase 1; Gene polymorphism; Haplotype; Multiple sclerosis; Restriction fragment length polymorphism

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1; SERINE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME ACTIVITY; EXON; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

2',5'-OLIGOADENYLATE SYNTHETASE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC;

EID: 33750710442     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00694.x     Document Type: Article

References (22)

1. Grigoriadis N, Hadjigeorgiou GM. Virus-mediated autoimmunity inmultiple sclerosis. J Autoimmune Dis 2006: 3: 1.
2. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993: 6: 382-427.
3. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol 2005: 15: 179-211.
4. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005: 4: 195-202.
5. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002: 3: 216-27.
6. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006: 7: 131-7.
7. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001: 14: 778-809.
8. Malathi K, Paranjape JM, Bulanova E et al. A transcriptional signaling pathway in the IFN system mediated by 2′-5′-oligoadenylate activation of RNase L. Proc Natl Acad Sci U S A 2005: 102: 14533-8.
9. Ghosh A, Sarkar SN, Rowe TM, Sen GC. A specific isozyme of 2′-5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001: 276: 25447-55.
10. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci U S A 2002: 99: 9322-7.
11. Kajaste-Rudnitski A, Mashimo T, Frenkiel MP, Guenet JL, Lucas M, Despres P. The 2′,5′-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J Biol Chem 2006: 281: 4624-37.
12. Sangster MY, Heliams DB, Mac Kenzie JS, Shellam GR. Genetic studies of flavivirus resistance in inbred strains derived from wild mice: evidence for a new resistance allele at the flavivirus resistance locus (Flv). J Virol 1993: 67: 340-7.
13. Bonnevie-Nielsen V, Field LL, Lu S et al. Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′ AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005: 76: 623-33.
14. Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 2005: 54: 1588-91.
15. Tessier MC, Qu HQ, Frechette R et al. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? J Med Genet 2006: 43: 129-32.
16. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003: 4: 411-9.
17. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983: 13: 227-31.
18. Herr M, Dudbridge F, Zavattari P et al. Evaluation of fine mapping strategies for a multifactorial disease locus: systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. Hum Mol Genet 2000: 9: 1291-301.
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005: 21: 263-5.
20. Becker T, Knapp M. Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet Epidemiol 2004: 27: 21-32.
21. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new maximum likelihood algorithm for haplotype-based association analysis: the SEM algorithm. Ann Hum Genet 2004: 68: 165-77.
22. Leyva L, Fernandez O, Fedetz M et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005: 163: 165-71.